- Home
- RLYB vs KALA Comparison
RLYB vs KALA Comparison
Compare RLYB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- KALA
- Stock Information
- Founded
- RLYB 2018
- KALA 2009
- Country
- RLYB United States
- KALA United States
- Employees
- RLYB N/A
- KALA N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- KALA Health Care
- Exchange
- RLYB Nasdaq
- KALA Nasdaq
- Market Cap
- RLYB 22.0M
- KALA 26.2M
- IPO Year
- RLYB 2021
- KALA 2017
- Fundamental
- Price
- RLYB $0.63
- KALA $9.21
- Analyst Decision
- RLYB Hold
- KALA Strong Buy
- Analyst Count
- RLYB 3
- KALA 2
- Target Price
- RLYB $15.00
- KALA $13.50
- AVG Volume (30 Days)
- RLYB 458.7K
- KALA 126.2K
- Earning Date
- RLYB 08-07-2025
- KALA 08-08-2025
- Dividend Yield
- RLYB N/A
- KALA N/A
- EPS Growth
- RLYB N/A
- KALA N/A
- EPS
- RLYB N/A
- KALA N/A
- Revenue
- RLYB $761,000.00
- KALA N/A
- Revenue This Year
- RLYB N/A
- KALA N/A
- Revenue Next Year
- RLYB N/A
- KALA N/A
- P/E Ratio
- RLYB N/A
- KALA N/A
- Revenue Growth
- RLYB 154.51
- KALA N/A
- 52 Week Low
- RLYB $0.22
- KALA $2.92
- 52 Week High
- RLYB $1.25
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- RLYB 64.03
- KALA 70.30
- Support Level
- RLYB $0.53
- KALA $7.71
- Resistance Level
- RLYB $0.65
- KALA $8.75
- Average True Range (ATR)
- RLYB 0.06
- KALA 0.69
- MACD
- RLYB 0.00
- KALA 0.05
- Stochastic Oscillator
- RLYB 90.44
- KALA 99.33
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.